- Previous Close
26.21 - Open
26.41 - Bid 25.65 x 100
- Ask 25.83 x 100
- Day's Range
25.45 - 26.69 - 52 Week Range
8.79 - 42.20 - Volume
627,281 - Avg. Volume
2,214,904 - Market Cap (intraday)
1.236B - Beta (5Y Monthly) -0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-2.83 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 13, 2012
- 1y Target Est
116.00
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
www.cassavasciences.comRecent News: SAVA
View More
Performance Overview: SAVA
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAVA
View MoreValuation Measures
Market Cap
1.26B
Enterprise Value
1.14B
Trailing P/E
--
Forward P/E
151.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.65
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.43%
Return on Equity (ttm)
-8.35%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.37M
Diluted EPS (ttm)
-2.83
Balance Sheet and Cash Flow
Total Cash (mrq)
207.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-45.25M
Research Analysis: SAVA
View MoreCompany Insights: SAVA
SAVA does not have Company Insights